Aarhus University Hospital
Glibenclamide in single oral dose does not reduce pain-free or maximal walking distance
Published in Cardiovascular Business Week, April 11th, 2006
"The oral hypoglycemic sulphonylurea glibenclamide stimulates endogenous insulin secretion through blockade of ATP-sensitive potassium (KATP ) channels on pancreatic beta cells, but also blocks cardiovascular KATP channels, leading to increased peripheral vascular resistance and reduced peripheral blood flow in non-diabetic subjects. Therefore, this study examined whether a single oral dose of glibenclamide adversely affected the pain-free or maximal walking distance in patients with intermittent...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- deCODE genetics
DeCODE genetics reports 2005 revenues of $44 million, up from $42.1 million for 2004 - Egalet
Egalet a/s secures US$27.6 million via financing co-led by Atlas Venture and Index Ventures - Mera Pharmaceuticals
Mera Pharmaceuticals announces first quarter revenue of $152,394 - TransMedics, Inc.
Medical device company TransMedics, Inc. raises $29.75 million in series C funding - A. Cardarelli Hospital, Naples
Carotid artery stiffness and C-reactive protein were linked to metabolic syndrome in obese - Aarhus University Hospital
Ischemic preconditioning causes biphasic pattern of ST elevation during repeat coronary occlusions - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
